Fact checked byMindy Valcarcel, MS

Read more

June 06, 2024
1 min read
Save

MD Anderson Cancer Center names new member of James P. Allison Institute

Fact checked byMindy Valcarcel, MS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Susan Bullman, PhD, has been named an associate member of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center.

Members of The Allison Institute — launched to foster groundbreaking science that integrates immunobiology across disciplines —work to combine laboratory and clinical insights to develop novel and synergetic therapies that enable cures for more patients, according to a press release.

Susan Bullman, PhD
Source: Fred Hutchinson Cancer Center

Bullman, also an associate professor of immunology at The University of Texas MD Anderson Cancer Center, will bring her expertise in examining how the intratumoral microbiome and immune microenvironment influence patient responses to immunotherapy, to help push the field “beyond understanding and manipulating the interaction between T cells and cancer cells toward multiple integrated areas that influence tumor immunity,” according to the release.

Her lab combines preclinical cancer models, molecular microbiology and in situ imaging with spatial and single-cell sequencing approaches to better comprehend microbial interactions with the tumor microenvironment, according to the release.

“We are committed to bringing in the world’s top minds to advance our work toward gaining a comprehensive understanding of the tumor immune response, and we are pleased to welcome [Dr. Bullman] to MD Anderson and to the Allison Institute,” James P. Allison, PhD, director of the institute and regental professor and chair of immunology at the center, said in the release.

“These new members bring diverse expertise and a commitment to driving forward discoveries that offer meaningful benefits for patients,” Giulio Draetta, MD, PhD, chief scientific officer at the center, said in the release. “I look forward to seeing how the talented clinicians and scientists within the Allison Institute work together and across MD Anderson to advance our mission to end cancer.”